Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia

Efficacy of Optimized Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia and Identification of Intestinal Microbiota Signature

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome

Who May Be Eligible (Plain English)

Who May Qualify: - Adult (≥18 years) - Monomicrobial EF-BSI - Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy - Written willing to sign a consent form Who Should NOT Join This Trial: - Short term (within 3 days from BSI) mortality - Other concomitant infection Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult (≥18 years) * Monomicrobial EF-BSI * Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy * Written informed consent Exclusion Criteria: * Short term (within 3 days from BSI) mortality * Other concomitant infection

Locations (4)

Ospedale Maggiore "Carlo Alberto Pizzardi" di Bologna
Bologna, Bologna, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy
Azienda Ospedaliero Universitaria di Catanzaro "Mater Domini"
Catanzaro, Catanzaro, Italy
Humanitas Research Hospital
Milan, Milano, Italy